Figure 1 presents the diagnosed prevalent cases of MS by type in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) in 2016.

Multiple sclerosis (MS) is a disease where the immune system attacks the protective sheath covering nerves and can cause significant disability, such as paralysis.

MS affects more than 2.1 million people worldwide. Several different types of MS exist, which include relapsing remitting (RRMS), in which flare-ups are followed by periods of remission and then relapse; primary progressive (PPMS), in which the disease progresses slowly without periods of remission; and secondary progressive (SPMS), in which the symptoms worsen steadily over time with no periods of remission.

The most common form of MS is RRMS, which has the lowest disease severity, but also lacks efficient treatment to effectively prevent the disease from progressing to the more severe forms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Courses of treatment depend on the classification of MS type.

GlobalData epidemiologists analyzed the epidemiological trends of MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and determined that RRMS is the most common MS type. In the UK and France, PPMS is the second most common MS type, whereas in the other markets analyzed, SPMS is the second most common type. The figure below presents the diagnosed prevalent cases of MS by types in both sexes and all ages in the 7MM in 2016.

See Also:

In the 7MM combined, GlobalData estimated there were 726,343 diagnosed prevalent cases of MS classified as RRMS, corresponding to 70% of all diagnosed prevalent cases. In the 5EU (France, Germany, Italy, Spain, and UK), RRMS accounted for 79% of all diagnosed prevalent cases of MS. The US alone has 241,253 cases of RRMS.

MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and balance problems. MS can occur at any age, but commonly affects people of ages 15–60 years.

This disease significantly impacts the most productive years of a person’s life. About 40% of RRMS patients will develop SPMS in 10–15 years, where neurological degeneration and disability worsens steadily over time.

However, GlobalData analysts identified that most existing disease-modifying treatments are not very effective in slowing down worsening of neurological damages or preventing disease progression. This is an area with especially high market potential, since the largest proportion of MS cases are RRMS and would benefit from therapy that effectively prevents disease worsening to SPMS.